{{medical}}
{{expand|time=2017-12-24T17:37:38+00:00}}
{{Drugbox
| verifiedrevid = 477869643
| IUPAC_name = benzo[d]isoxazol-3-ylmethanesulfonamide
| image = Zonisamide2DACS.svg

| width = 200
| image2 = Zonisamide3Dan.gif

| width2 = 225

<!--Clinical data-->
| tradename = Zonegran
| Drugs.com = {{drugs.com|monograph|zonisamide}}
| MedlinePlus = a603008

| pregnancy_AU = D
| pregnancy_US = C

| legal_AU = S4

| legal_CA = Rx-only

| legal_UK = POM

| legal_US = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = ~100%<ref name = TGA>{{cite web|title=Zonegran® Product Information|work=TGA eBusiness Services|publisher=SciGen (Australia) Pty Ltd|date=4 April 2013|accessdate=18 November 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02002-3|format=PDF|archive-date=2018-10-15|archive-url=https://web.archive.org/web/20181015231609/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02002-3|dead-url=no}}</ref>
| protein_bound = 40%<ref name = TGA/>
| metabolism = [[Hepatic|Hepatic]] through [[CYP3A4|CYP3A4]]<ref name = TGA/>
| elimination_half-life = 63 hours in [[Blood_plasma|plasma]]<ref name = TGA/>
| excretion = [[Renal|Renal]] (62%); Faeces (3%)<ref name = TGA/>

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 68291-97-4
| ATC_prefix = N03
| ATC_suffix = AX15
| PubChem = 5734
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00909
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5532
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 459384H98V
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00538
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 10127
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 750
| PDB_ligand = ZON

<!--Chemical data-->
| C=8 | H=8 | N=2 | O=3 | S=1 
| molecular_weight = 212.227 g/mol
| smiles = O=S(=O)(N)Cc2noc1ccccc12
| InChI = 1/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
| InChIKey = UBQNRHZMVUUOMG-UHFFFAOYAZ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UBQNRHZMVUUOMG-UHFFFAOYSA-N
| melting_point = 162
}}
'''唑尼沙胺'''（{{lang-en|Zonisamide}}）是一种[[磺胺类药物|磺胺类]]{{le|抗惊厥药|anticonvulsant}}，被批准用于辅助治疗成人的[[癫痫发作|癫痫发作]]，婴儿的[[韋斯特綜合症|韋斯特綜合症]]，{{le|伦诺克斯-加斯托二氏综合征|Lennox-Gastaut syndrome}}、{{le|肌阵挛|myoclonic}}和全身[[强直－阵挛性发作|强直－阵挛性发作]]<ref>Comprehensive Pharmacy Review, Leon Shargel, 6th edition, p988</ref>。

==参考文献==
{{Reflist|2}}

==外部链接==
*[http://www.eisai.com// Official Eisai Website]{{Wayback|url=http://www.eisai.com// |date=20201210222558 }}
*[http://med.ds-pharma.co.jp/medicine/ryouiki/seishin/doc/excegran_tabpow_tenpu.pdf Dainippon Sumitomo Prescribing Information for Excegran]{{dead link|date=2017年12月 |bot=InternetArchiveBot |fix-attempted=yes }} (Japanese version)
*[https://web.archive.org/web/20060116015705/http://www.ds-pharma.co.jp/english/ Official Dainippon Sumitomo Pharma Website] (English version)

{{抗癫痫药}}
{{抗肥胖制剂}}

[[Category:抗痉挛药物|Category:抗痉挛药物]]
[[Category:碳酸酐酶抑制剂|Category:碳酸酐酶抑制剂]]
[[Category:磺胺|Category:磺胺]]